article · Frontiers in Pharmacology
The abstract on record is too brief for a reliable plain-language summary, so none has been generated.
Cis Ls and Ant Ls delivery strategy mitigates liver and kidney damage while enhancing anticancer efficacy against EAC.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3389/fphar.2025.1659575
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.